Editorial: Nanotechnology and Biomaterials for Cell and Drug Therapy.

Curr Pharm Des

Institute on Membrane Technology, National Research Council of Italy, ITM-CNR c/o University of Calabria, Via P. Bucci cubo 17/C I-87036 Rende (CS). Italy.

Published: June 2018

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161282326171003091947DOI Listing

Publication Analysis

Top Keywords

editorial nanotechnology
4
nanotechnology biomaterials
4
biomaterials cell
4
cell drug
4
drug therapy
4
editorial
1
biomaterials
1
cell
1
drug
1
therapy
1

Similar Publications

Nanotechnology-Based Drug Delivery Systems, 2nd Edition.

Pharmaceutics

January 2025

Department of Technology of Chemical-Pharmaceutical and Cosmetic Substances, D. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russia.

Nanotechnology is a promising and rapidly developing area in the 21st century, which affects various fields of science: physics, chemistry, biology, engineering, microelectronics, and medicine [...

View Article and Find Full Text PDF

Properties and Applications of Nanoparticles and Nanomaterials.

Int J Mol Sci

January 2025

Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing 100084, China.

Nanomaterials have rapidly developed and attention surrounding their use has increased in recent years [...

View Article and Find Full Text PDF

Recent Advances in the Evaluation of the Toxicological and Ecotoxicological Risks of Polymer, Zinc Oxide, Titanium Dioxide and Graphene Oxide Nanoparticles.

Nanomaterials (Basel)

January 2025

Department Biochemistry & Physiology, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.

Nanotechnology has substantial potential for advancements in the fields of biology and medicine [...

View Article and Find Full Text PDF

Introduction: Extracellular vesicles (EVs) can potently inhibit inflammation yet there is a lack of understanding about the impact of donor characteristics on the efficacy of EVs. The goal of this study was to determine whether the sex and age of donor platelet-derived EVs (PEV) affected their ability to inhibit viral myocarditis.

Methods: PEV, isolated from men and women of all ages, was compared to PEV obtained from women under 50 years of age, which we termed premenopausal PEV (pmPEV).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!